- Home
- »
- Meetings
- »
- Industry/Academia Translational Oncology Symposium 2013
- »
- Cancer Treatment with NK Cell Lines: An Effective Alternative?
Cancer Treatment with NK Cell Lines: An Effective Alternative?
Armand Keating, MD, FCRP(C), University of Toronto, Princess Margaret Hospital
| April 11, 2013 | |
| 33 minutes | |
| Armand Keating | |
Armand Keating, MD, FCRP(C), is Professor of Medicine, Director , Division of Hematology, Epstein Chair in Cell Therapy and Transplantation and a Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. He is also Director of the Cell Therapy Program and the Orsino Cell Therapy Translational Research Laboratory at Princess Margaret Hospital and a Senior Scientist in Experimental Therapeutics at the Toronto General Research Institute.
Dr. Keating’s clinical and research interests focus on anti-cancer cell therapy, blood and marrow transplantation, leukemia, lymphoma, and cell-based tissue regeneration. He has conducted laboratory, translational and clinical research in cell therapy, normal and leukemic hematopoiesis, and on the biology and clinical application of mesenchymal stromal cells.
